Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

  • Karim Fizazi, M.D.,
  • Neal Shore, M.D.,
  • Teuvo L. Tammela, M.D., Ph.D.,
  • Albertas Ulys, M.D.,
  • Egils Vjaters, M.D.,
  • Sergey Polyakov, M.D.,
  • Mindaugas Jievaltas, M.D.,
  • Murilo Luz, M.D.,
  • Boris Alekseev, M.D.,
  • Iris Kuss, M.D.,
  • Christian Kappeler, Ph.D.,
  • Amir Snapir, M.D., Ph.D.,
  • Toni Sarapohja, M.Sc.,
  • and Matthew R. Smith, M.D., Ph.D.
  • for the ARAMIS Investigators*

    Background- Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. We evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer.

click here to read more….

 

 

By | February 18th, 2019|